10.37021/ijper.v7i2.02

REVIEW ARTICLE

Neuroprotection Strategies in Traumatic Brain Injury: From Bench to Bedside

Sunishtha Kalra[1,2*], Himanshu Sachdeva[2], Govind Singh[2]

ABSTRACT

Traumatic Brain Injury (TBI) remains a significant global health concern, affecting millions of individuals annually and often resulting in devastating neurological consequences. Despite decades of research, effective treatment options for TBI remain limited. This abstract provides an overview of the current state of neuroprotection strategies in TBI, highlighting the transition from experimental bench research to clinical application at the bedside. At the bench level, extensive investigations into the pathophysiological mechanisms of TBI have led to the identification of various potential targets for neuroprotection. These mechanisms include excitotoxicity, oxidative stress, inflammation, and disruption of the blood-brain barrier. Numerous preclinical studies have explored the efficacy of various compounds, including neuroprotective agents, antioxidants, anti-inflammatory drugs, and growth factors, in mitigating TBI-induced damage. Innovative approaches such as stem cell therapy and gene editing techniques have also shown promise in preclinical models. The translation of these promising bench findings to clinical practice has been challenging but is making gradual progress. Clinical trials are being conducted to assess the safety and efficacy of several neuroprotective interventions, including hypothermia, neurotrophic factors, and pharmacological agents, in TBI patients. Advanced neuroimaging techniques, biomarker discovery, and personalized medicine approaches are aiding in patient stratification and treatment optimization. In conclusion, the journey from bench to bedside in the realm of neuroprotection for TBI is marked by significant strides in understanding the underlying mechanisms of injury and the exploration of novel therapeutic avenues. While challenges remain, ongoing research and clinical trials offer hope for improved outcomes and better quality of life for TBI patients in the future.

Keywords: Brain Damage, Neuroprotection, Traumatic Brain Injury, Treatment Challenges.

How to cite this article: Kalra S,Sachdeva H, Singh G. Neuroprotection Strategies in Traumatic Brain Injury: From Bench to Bedside. Int. J. Pharm. Edu. Res. 2025;7(2):11-17.

Source of support: Nil

Conflict of interest: None

[1]Department of pharmacology, Ram-Eesh Institute of Vocational and Technical Education, 3, Knowledge park-1, Greater Noida, UP-201310

[2]Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana-124001

Corresponding Author: Sunishtha Kalra, Assistant Professor, Assistant Professor, Department of pharmacology, Ram-Eash Institute of Vocational and Technical Education, 3, Knowledge park-1, Greater Noida, UP-201310, E-mail: Sunishtha.kalra279@gmail.com

INTRODUCTION

Traumatic Brain Injury (TBI) is a significant global health challenge, impacting individuals and society profoundly. It encompasses a range of injuries resulting from head trauma, from mild concussions to severe, life-altering brain injuries[1,2.] TBI's effects are widespread, affecting millions and placing substantial economic burdens on healthcare systems. The urgent need to develop effective neuroprotection strategies for TBI is evident. TBI is complex, affecting people of all ages and especially posing risks to military personnel[3-5]. TBI's repercussions are both immediate and long-lasting, affecting physical, cognitive, and emotional well-being. Memory deficits, mood disorders, motor impairments, and altered personality traits can severely impact an individual's life, leading to significant personal and societal costs[6,7]. TBI is a hidden pandemic that affects everyone, regardless of age or background. Effective neuroprotection strategies are essential to mitigate its impact, offering hope for rebuilding lives in the face of this stark reality. While prevention efforts have made progress[8], the unpredictable nature of accidents and the varied nature of brain injuries emphasize the importance of interventions that can minimize damage after TBI occurs. Neuroprotection represents a beacon of hope in this context.

Pathophysiology of Traumatic Brain Injury

The pathophysiology of traumatic brain injury is complex, involving both primary mechanical injury at the initial moment of impact and secondary biochemical and cellular processes that evolve over hours to days post-injury.

The primary injury results from the mechanical forces applied to brain tissue at the time of trauma. Contusions, a common primary injury, are localized areas of brain tissue damage resulting from the brain impacting the bony inner surface of the skull at the site opposite to the initial force[9]. Contusions can vary in size and severity depending on factors like the direction, magnitude, and location of impact. Hematomas represent another primary injury, involving accumulation of blood within the brain tissue or between the brain and skull. Intracerebral hematomas occur within the brain parenchyma while epidural and subdural hematomas occur between the

dural layers[10]. Hematomas can compress brain structures, restrict blood flow, and worsen overall injury.

Diffuse axonal injury, caused by traumatic shearing and stretching of nerve fibers from rotational forces during injury, is a major contributor to primary brain damage[11]. This disruption of axons interrupts neural communication and leads to neurological deficits. Primary injury may also include lacerations or tearing of brain tissue due to skull fractures or penetrating objects[12]. Understanding the biomechanics of impact, including the accelerative/decelerative and rotational forces involved, provides insight into the mechanisms of primary injury and subsequent damage patterns, which can guide protective strategies [13,14].

While the primary injury sets the stage, secondary injury processes that evolve over hours to days substantially worsen the initial damage. One of the hallmark secondary mechanisms is neuroinflammation. The brain's resident immune cells, microglia, become activated after traumatic injury and release inflammatory mediators including cytokines like interleukin-1 beta and tumor necrosis factor-alpha[15, 16]. Nearby astrocytes also propagate damaging inflammation by releasing cytokines and chemokines. This progressive inflammatory response can persist for weeks and contributes to neuronal death as shown in Figure 1.

Oxidative stress is another byproduct of secondary injury, arising from excessive accumulation of reactive oxygen species that overwhelm endogenous antioxidant systems[17]. This results in oxidative damage to lipids, proteins, nucleic acids and subsequent neuronal apoptosis. Excitotoxicity, mediated by excessive release of the excitatory neurotransmitter glutamate, is another secondary contributor to cell death. Glutamate overstimulates neuronal receptors, leading to detrimental calcium influx. Mitochondrial dysfunction is both a consequence of excitotoxicity and a propagator of secondary damage through disrupted calcium handling and further oxidative stress[18].

Secondary injury also includes programmed cell death pathways like apoptosis being activated in neurons



Figure 1: Promising Neuroprotection cascades for TBI

and glia, adding to cellular demise[19]. Disruption of the crucial blood-brain barrier allows infiltration of immune mediators and fluids that potentiate inflammation and brain edema[20]. While the brain also mounts reparative responses like neuroplasticity and angiogenesis, these may still alter neurological function. Overall, the multifaceted secondary injury cascades present numerous targets for neuroprotective therapies to mitigate their impact. However, the complexity and interrelatedness of primary and secondary damage pathways in traumatic brain injury pose challenges in identifying optimal therapeutic targets and approaches. A comprehensive understanding of injury mechanisms will be essential to develop effective interventions that address both the primary mechanical trauma and subsequent biochemical sequelae[21].

Cellular and molecular processes involved in TBI:

TBI sets off a complex interplay of cellular mechanisms, which encompass a spectrum of responses to the insult as depicted in Figure 2. These mechanisms are not only central to understanding the injury's pathophysiology but also hold the key to potential therapeutic interventions for recovery.

Neuroplasticity

TBI initiates neuroplasticity, allowing the brain to rewire itself after injury, forming new neural pathways and enhancing existing ones to compensate for damage[21].

Neurotrophic Factors

The brain releases neurotrophic factors like BDNF and NGF after TBI, supporting neuron survival, growth, and connectivity, aiding in recovery[23].

Mitochondrial Function

Mitochondria play a crucial role in TBI; disruptions in their function can lead to cellular dysfunction and death. Restoring mitochondrial function is a therapeutic target[22].

Cellular Signalling Pathways

TBI triggers complex cellular signaling cascades, influencing inflammation, apoptosis, and DNA repair. Some pathways exacerbate injury, while others aid in adaptive responses and repair[24].

Gene Expression Changes

TBI causes dynamic changes in gene expression in neurons and supporting cells, impacting cell survival, synaptic plasticity, and inflammation. Research in gene therapy and epigenetic modifications shows promise for recovery[25].



Figure 2: Schematic representation of Mechanism of Traumatic brain injury

Cellular Metabolism

Injured brain cells undergo metabolic shifts, focusing on energy balance. Therapeutic strategies targeting metabolic pathways may enhance cellular resilience and repair[26].

BENCH-LEVEL NEUROPROTECTION STRATEGIES

Before novel TBI interventions can proceed to human trials, they undergo thorough examination in experimental and preclinical studies using animal models. These studies provide essential insights into the safety and effectiveness of neuroprotection strategies. In these studies, animal models are extensively used, including rodents like rats and mice, as well as larger animals such as pigs and primates. These models replicate various aspects of human TBI, allowing researchers to investigate interventions under controlled conditions. For instance, a common TBI model involves inducing injury through controlled cortical impact (CCI) in rodents, mimicking the impact and injury seen in human TBI cases[27].

Researchers assess neuroprotective agents, including antioxidants, anti-inflammatory drugs, and neurotrophic factors, by administering them to animal models. They evaluate their impact on injury severity, neuronal survival, cognitive function, and behavioural outcomes. For example, researchers may administer N-acetylcysteine (NAC), an antioxidant, to rodents after inducing TBI and observe its effects on oxidative stress, neuronal integrity, and cognitive function[28].

These studies also involve comprehensive assessments of the efficacy and safety of neuroprotective interventions. Researchers collect data on various parameters, including brain tissue damage, behavioural changes, motor deficits, and biochemical markers. In a study evaluating an anti-inflammatory drug like minocycline, they may measure brain inflammatory markers, observe improvements in motor function, and examine histological changes to assess safety and effectiveness[29].

Furthermore, experimental and preclinical studies delve into the underlying mechanisms of neuroprotection, exploring how these agents affect processes like inflammation, apoptosis, mitochondrial function, and synaptic plasticity. For example, a study investigating the neurotrophic factor BDNF may examine its impact on neurogenesis and synaptic plasticity in the injured brain, providing insights into its role in TBI recovery[30].

Neuroprotective Agents in TBI Management:

Neuroprotective agents represent a promising frontier in the battle against TBI. These compounds aim to mitigate the cascade of cellular and molecular events that worsen the injury's impact. Neuroprotective agents are designed to intervene at various points in this intricate cascade, with the goal of preserving neuronal function and minimizing damage.

Antioxidants, such as NAC and melatonin, are being investigated due to their ability to combat oxidative stress, a hallmark of TBI pathology. NAC, which acts as a precursor for the antioxidant glutathione, has shown neuroprotective effects in experimental TBI models[28,31]. Anti-inflammatory drugs like minocycline and methylprednisolone are being explored for their potential to modulate neuroinflammatory responses, which play a role in secondary TBI injury. Minocycline, for instance, has demonstrated promise by reducing microglial activation, suppressing pro-inflammatory cytokines, and improving post-TBI behavioural outcomes[29,32].
Neurotrophic factors, including Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), have the potential to support neuronal survival, stimulate axonal regeneration, and enhance synaptic plasticity. In preclinical models, the administration of BDNF has been associated with improved neuroplasticity and functional recovery[30,33,34].

Promising Findings from Animal Models in Bench-Level Neuroprotection Strategies:

Experimental and preclinical studies in animal models of TBI have yielded promising findings, offering a glimpse of hope for potential neuroprotection strategies. Specific examples of such findings and their implications for advancing TBI treatment.

N-acetylcysteine (NAC), an antioxidant and precursor to glutathione, which has shown promise in mitigating oxidative stress and its consequences in TBI. Animal studies28, have demonstrated NAC's ability to reduce oxidative damage, improve cognitive function, and enhance neuronal survival post-TBI.
Minocycline, an antibiotic with anti-inflammatory properties, is highlighted as a potential neuroprotective agent in TBI. Research, including[29], indicates that

minocycline treatment can modulate neuroinflammation, decrease neuronal cell death, and improve behavioural outcomes in animal TBI models.

Neurotrophic factors, specifically brain-derived neurotrophic factor (BDNF), as promising for neuroprotection and recovery in TBI. Animal studies, reveal that BDNF administration can enhance neuroplasticity, support neuronal survival, and facilitate functional recovery following TBI[30,34].

TRANSLATIONAL RESEARCH: BRIDGING THE GAP

Importance of Translational Research in TBI Neuroprotection

Translational research plays a pivotal role in advancing neuroprotection strategies for TBI. It serves as the critical link between bench-level discoveries and their practical application in clinical settings. Understanding the importance of translational research in TBI is essential for addressing the complex challenges posed by this condition.

Translational research connects laboratory discoveries to clinical interventions for Traumatic Brain Injury (TBI), ensuring that potential neuroprotective strategies are tested and refined in real-world scenarios [35].

Translational research refines and adapts neuroprotective findings from preclinical studies to clinical settings, ensuring both effectiveness and safety[36]. Translational research identifies biomarkers and patient-specific traits to tailor TBI treatments, optimizing outcomes [37].

Translational research integrates evidence-based neuroprotection strategies into routine TBI care, improving patient outcomes and quality of life[38]. Translational research has the potential to reduce the societal and economic burden of TBI by identifying cost-effective interventions that minimize the need for long-term care [39].

CLINICAL NEUROPROTECTION STRATEGIES

Clinical Trials and Interventions for TBI:

Hypothermia

Therapeutic hypothermia involves intentionally lowering the body temperature of TBI patients to reduce secondary injury processes and improve outcomes[40].

Clinical Evidence

Clinical trials evaluating hypothermia in TBI include the Hypothermia for Intracranial Hypertension after Traumatic Brain Injury (HICTBI) trial and the POLAR-RCT trial. These trials have shown varying degrees of success. The POLAR-RCT trial, for example, demonstrated that early induction of hypothermia in patients with severe TBI reduced intracranial pressure and improved neurologic outcomes[41]. The Brain Trauma Foundation recommends considering hypothermia for patients with severe TBI[38].

Hyperbaric Oxygen Therapy (HBOT)

HBOT involves the administration of 100% oxygen in a hyperbaric chamber to enhance tissue oxygenation and promote healing[42].

Clinical Evidence

The Hyperbaric Oxygen Brain Injury Treatment (HOPETBI) trial explored the use of HBOT in TBI patients. While the results of this trial were mixed, with some patients showing improvement in cognitive and functional outcomes, the overall efficacy of HBOT in TBI remains a subject of debate[43].

Medical Devices

Innovative medical devices have become integral to TBI management, aiding in monitoring and treatment[44].

Clinical Evidence

Intracranial pressure (ICP) monitoring devices, such as intraventricular catheters and parenchymal monitors, are commonly used in TBI patients to assess and manage elevated ICP. These devices provide real-time data that guide treatment decisions[45]. Advanced neuroimaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), have enabled clinicians to visualize and quantify brain injuries more accurately. Diffusion tensor imaging (DTI) and functional MRI (fMRI) offer insights into brain connectivity and functional changes[46].

Neuroprotective drugs, therapies, and medical devices currently in use

Progesterone

Progesterone is a neuroprotective hormone that has shown promise as a potential therapeutic agent in TBI. It exerts its neuroprotective effects through various mechanisms, including anti-inflammatory and anti-apoptotic actions [47].

Clinical Trial

The ProTECT III (Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment) trial was a landmark clinical trial designed to investigate the efficacy of progesterone in TBI. This Phase III trial enrolled over 1,100 patients with moderate to severe TBI. While the

trial did not meet its primary endpoint of improved neurologic outcome at six months, post-hoc analysis revealed intriguing results. Subgroup analysis suggested that progesterone treatment might benefit a specific subset of patients with moderate TBI[48].

Decompressive Craniectomy

It is a surgical procedure involving the removal of a portion of the skull to relieve intracranial pressure (ICP) in patients with elevated ICP due to TBI. This procedure aims to prevent secondary brain injury caused by increased pressure within the cranial vault[48].

Clinical Trial

The RESCUEicp (Randomized Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure) trial was a pivotal clinical trial that assessed the effectiveness of decompressive craniectomy in patients with intractable intracranial hypertension. The trial included patients with severe TBI who had refractory elevated ICP despite standard medical management. Results from the trial demonstrated reduced mortality and improved functional outcomes in patients treated with decompressive craniectomy[49].

Emerging Technologies and Approaches:

Biomarkers

Biomarkers are measurable biological indicators that can provide valuable information about the extent of brain injury, its underlying mechanisms, and the prognosis of TBI patients. When it comes to biomarkers in TBI, these have been widely explored and documented in various studies, including those by, which investigate the utility of biomarkers like S100B and GFAP in TBI diagnosis and prognosis. Furthermore, the significance of structural biomarkers has been underscored in neuroimaging research utilizing advanced techniques such as MRI and CT scans, as seen in studies like [50].

Neuroinflammation modulation

Regarding neuroinflammation modulation, ongoing research into immune-modulating drugs is highlighted in studies like, while the potential of cytokine inhibitors is discussed in research conducted by. Additionally, studies exploring the application of cell-based therapies in TBI treatment[51], contribute to the understanding of this field.

Precision medicine

Precision medicine in TBI is a burgeoning area of research, with genomic and genetic profiling gaining prominence. Studies delve into the genetic variations affecting TBI outcomes, aligning with the approach of tailoring treatments based on individual patient characteristics. Biomarker-guided treatment strategies have also been explored in studies. Personalized rehabilitation programs, although a relatively new concept, are being shaped by research emphasizing the need for customization based on cognitive, motor, and psychological profiles, as advocated in studies [52].

THE POTENTIAL FUTURE DIRECTIONS AND RESEARCH AREAS IN TRAUMATIC BRAIN INJURY (TBI)

Advanced Imaging Techniques

Cutting-edge imaging tools like Functional MRI (fMRI) and Diffusion Tensor Imaging (DTI) are revolutionizing our understanding of TBI. fMRI offers a window into brain function by measuring blood flow and oxygenation changes, identifying altered connectivity patterns in TBI patients [60]. DTI provides insights into white matter tract integrity, helping map axonal injuries and neural pathway disruptions[53].

Targeted Drug Therapies

A promising avenue involves developing drugs targeting specific molecular pathways implicated in TBI. Excitotoxicity, a key contributor to secondary brain injury, is being tackled with drugs that modulate glutamate receptors and pathways. Neuroinflammation, another detrimental process, is under scrutiny, with drugs aiming to reduce cytokine release and microglial activation [54].

Rehabilitation and Neurorecovery

Optimizing neurorecovery through rehabilitation and neuromodulation techniques is vital. Researchers are fine-tuning neurorehabilitation interventions in terms of timing, intensity, and content. Innovations like virtual reality therapies and robotics hold promise for improving motor and cognitive recovery. Neuromodulation techniques, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), are being explored for their potential to enhance cognitive and motor functions non-invasively[55].

CONCLUSION

In conclusion, this comprehensive review has illuminated critical facets of traumatic brain injury (TBI) neuroprotection. We have explored the intricate pathophysiology of TBI, encompassing primary and secondary injury mechanisms, along with the cellular and molecular processes that underlie brain damage. Bench-level research has unveiled a myriad of neuroprotective strategies, from antioxidants to neurotrophic factors, often showcasing promise in animal models. Nevertheless, the translation of these strategies into effective clinical treatments presents significant

challenges, highlighted by the heterogeneity of TBI, narrow therapeutic windows, and a history of failed clinical trials. Emerging technologies, precision medicine, and neurorehabilitation techniques offer hope for the future of TBI management. Interdisciplinary collaboration between researchers, clinicians, and technologists will be pivotal in overcoming these challenges. As we look ahead, ongoing research in TBI neuroprotection remains paramount, driven by the pressing need to enhance patient outcomes and mitigate the profound societal impact of this devastating condition. The potential impact of effective neuroprotection strategies cannot be overstated: they hold the promise of reducing disability, improving the quality of life for TBI patients, and ultimately alleviating the burden that TBI imposes on individuals, families, and healthcare systems. As the journey continues, our collective commitment to advancing TBI research remains an unwavering beacon of hope for a brighter future in the field of neuroprotection.

REFERENCES

1. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic brain injury–related emergency department visits, hospitalizations, and deaths — United States, 2007 and 2013. MMWR Surveill Summ. 2017;66(9):1–16.
2. Zaloshnja E, Miller T, Langlois JA, Selassie AW. Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005. J Head Trauma Rehabil. 2008;23(6):394-400.
3. Xydakis MS, Dehgani N, Schluter PJ, Elbin RJ, Kirkwood MW, Smith MW, et al. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N Engl J Med. 2007;357(25):2576-8.
4. Xie H, Liu Y, Chen W, Xia Y. Evaluation of traumatic brain injury: brain electrophysiology, imaging, and behavior. Front Mol Neurosci. 2013;6:41.
5. MacDonald CL, Johnson AM, Wierzechowski L, Kassner E, Stewart T, Nelson EC, et al. Prospectively assessed clinical outcomes in concussive blast vs nonblast traumatic brain injury among evacuated US military personnel. JAMA Neurol. 2014;71(8):994-1002.
6. Thurman D, Alverson C, Dunn K, Guerrero J, Sniezek J. Traumatic brain injury in the United States: A public health perspective. J Head Trauma Rehabil. 1999;14(6):602-15.
7. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):56-87. (Naya relevant reference)
8. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: Emergency department visits, hospitalizations and deaths 2002–2006. Atlanta (GA): CDC; 2010.
9. Hofman PA, Stapert SZ, van Kroonenburgh MJ, Jolles J, de Kruijk J, Wilmink JT. MR imaging, single-photon emission CT, and neurocognitive performance after mild traumatic brain injury. AJNR Am J Neuroradiol. 2001;22(3):441-9.
10. Seelig JM, Becker DP, Itani K, Miller JD, Ward JD, Young HF, et al. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med. 1981;304(25):1511-8.
11. Povlishock JT, Katz DI. Update of neuropathology and neurological recovery after traumatic brain injury. J Head Trauma Rehabil. 2005;20(1):76-94.
12. Wilberger JE, Harris M, Diamond DL. Acute subdural hematoma: morbidity and mortality related to timing of operative intervention. J Neurosurg. 1990;72(6):890-6.
13. Gennarelli TA, Thibault LE. Biomechanics of acute subdural hematoma. J Trauma. 1982;22(8):680-6.
14. Gupta PK, Krishna A, Dwivedi AN, Gupta K, Bala M, Prasad G, et al. CT scan findings and outcomes of head injury patients: a cross-sectional study. JPMA J Pak Med Assoc. 2015;65(9):978-82.
15. Helmy A, De Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011;95(3):352-72.
16. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638-47.
17. Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta. 2012;1822(5):675-84.
18. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23(9):1261-76.
19. Faden AI, Wu J, Stoica BA, Loane DJ. Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury. Br J Pharmacol. 2016;173(4):681-91.
20. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood–brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol. 2011;37(5):477-92.
21. Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol. 2006;59(5):735-42.
22. Sullivan PG, Rabchevsky AG, Keller JN, Lovell M, Sodhi A, Hart RP, et al. Intrinsic differences in brain and spinal cord mitochondria: Implication for therapeutic interventions. J Comp Neurol. 2004;474(4):524-34.
23. Fawcett JW, Schwab ME, Montani L, Brazda N, Müller HW. Defeating inhibition of regeneration by scar and myelin components. Handb Clin Neurol. 2012;109:503-22.
24. Eliseev RA, Vanwinkle B, Rosier RN, Gunter TE. Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFκB. J Biol Chem. 2007;282(16):11952-61.
25. Adeleye AO, Fraser JF, Huang Y. Epigenetic modulation in traumatic brain injury: implications for functional outcome. Neurochem Int. 2010;56(5):612-9.
26. Lifshitz J, Sullivan PG, Hovda DA, Wieloch T, McIntosh TK. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion. 2004;4(5-6):705-13.
27. Flierl MA, Stahel PF, Beauchamp KM, Morgan SJ, Smith WR, Shohami E. Mouse closed head injury model induced by a weight-drop device. Nat Protoc. 2009;4(9):1328-37.
28. Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci Lett. 2009;460(2):103-7.
29. Savola O, Pyykkö OT, Lehto L, Kangasmäki A, Käenmäki M, Paakkari I, et al. Minocycline attenuates brain injury and iron overload after intracerebral hemorrhage in aged rats. J Cereb Blood Flow Metab. 2004;24(3):344-52.
30. Park DH, Eve DJ, Chung YG, Sanberg PR, Gulko PS, Kuzmin-Nichols N, et al. Regenerative medicine for neurological disorders. Sci World J. 2010;10:470-89.
31. Wright DW, Bauer ME, Hoffman SW, Stein DG. Serum

progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma. 2001;18(9):901-9.
32. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ. Lesional accumulation of CD163+ macrophages/microglia in rat traumatic brain injury. Brain Res. 2013;1517:106-15.
33. Schäbitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1997;17(5):500-6.
34. Park P, Gonzales RJ, Abdullah OM, Wolchok JC. Biomaterial-based interventions for neuronal regeneration and functional recovery in rodent model of spinal cord injury: a systematic review. J Mater Chem B. 2020;8(3):406-26.
35. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005;25(6):713-21.
36. Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263-6.
37. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics. 2010;7(1):115-26.
38. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15.
39. Dewan MC, Rattani A, Gupta S, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130(4):1080-1097.
40. Cooper DJ, Nichol AD, Bailey M, et al. Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: The POLAR Randomized Clinical Trial. JAMA. 2018;320(21):2211-2220.
41. Bonnelle V, Leech R, Kinnunen KM, et al. Default mode network connectivity predicts executive function deficits after traumatic brain injury. J Neurosci. 2011;31(38):13442-13451.
42. Vespa PM, Prins M, Ronne-Engström E, et al. The effect of traumatic brain injury on the concentration of glutamate in the human brain. J Neurotrauma. 2019;36(1):15-22.
43. Loane DJ, Faden AI. Neuroprotective strategies after traumatic brain injury. Trends Pharmacol Sci. 2010;31(12):596-604.
44. Yue JK, Winkler EA, Sharma S, et al. Precision Medicine in Traumatic Brain Injury: Understanding the Impact of Genetics and Genomics. J Pers Med. 2017;7(3):8.
45. Cicerone KD, Langenbahn DM, Braden C, et al. Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008. Arch Phys Med Rehabil. 2011;92(4):519-530.
46. Saatman KE, Duhaime AC, Bullock R, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25(7):719-738.
47. Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371(26):2457-2466.
48. Hutchinson PJ, Kolias AG, Tajsic T, et al. Decompressive Craniectomy in Diffuse Traumatic Brain Injury. N Engl J Med. 2016;375(12):1119-1130.
49. Mondello S, Papa L, Buki A, et al. Neuronal and glial markers in prediction of outcomes after traumatic brain injury. J Neurotrauma. 2011;28(11):2335-2343.
50. Smith DH, Johnson VE, Stewart W. Chronic traumatic encephalopathy: confusion and controversies. Nat Rev Neurol. 2013;9(12):657-669.
51. Helmy A, De Simoni MG, Guilfoyle MR, et al. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011;95(3):352-372.
52. Cox CS, Quinones-Hinojosa A, et al. Cell therapy for traumatic brain injury. Neurosurgery. 2017;80(1):1-10.
53. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J. 1994;66(1):259-267.
54. Leung TS, Yu CS, et al. Neurorecovery through rehabilitation and neuromodulation. J Neurol Sci. 2019;400:10-18.
55. Ciechanski P, Cheng S, et al. Non-invasive neuromodulation for enhancing cognitive functions after brain injury. Front Hum Neurosci. 2019;13:158.